Clicky

Eupraxia Pharmaceuticals Inc(EPRX)

Description: Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate, EP-104IAR, that is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treatment of canine and equine osteoarthritis. Its products in development also include EP-201, a product candidate for prophylaxis of post-surgical infections; and EP-105, an extended-release product candidate for the local delivery of anesthetics to treat post-surgical pain. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was founded in 2012 and is headquartered in Victoria, Canada.


Keywords: Biotechnology Life Sciences Pain Arthritis Osteoarthritis Skeletal Disorders Knee Osteoarthritis Biotechnology Sector Canine And Equine Osteoarthritis Ep 104 Iar Eupraxia

Home Page: www.eupraxiapharma.com

EPRX Technical Analysis

2067 Cadboro Bay Road
Victoria, BC V8R 5G4
Canada
Phone: 250 590 3968


Officers

Name Title
Dr. James A. Helliwell FRCPC, M.D. CEO & Director
Mr. Bruce G. Cousins CPA, C.A., CPA Pres & CFO
Dr. Amanda Malone Ph.D. Chief Scientific Officer
Mr. Paul Anthony Brennan B.Sc., M.Sc. Chief Bus. Officer

Exchange: TO

Country: CA : Canada

Currency: Canadian Dollar (C$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.9074
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: December
Full Time Employees: 19
Back to stocks